Biointron Reports Wet-Lab Validation Results for Molence Bio's AI-Designed Mol-1 Antibodies Using RushDATA
· GlobeWire Daily Editorial Desk · Source: www.prnewswire.com

Image: Biointron · Photo source · Resized and letterboxed to 16:9; no AI generation
Biointron Biological USA Inc. reported the results of wet-lab validation assays for AI-designed antibodies generated by Molence Bio's Mol-1 project. Using its RushDATA service, Biointron evaluated developability properties for candidates designed by the open model.
According to the announcement published on November 13, 2026, 23 out of 30 AI-designed candidates met at least three of the four tested developability criteria.
Developability Assessment and Benchmarking
AI-designed antibodies require experimental validation to confirm properties related to manufacturability and safety. Biointron conducted developability panels on VHH-Fc candidates from Molence Bio, measuring:
- Hydrophobicity
- Thermal stability
- Self-interaction
- Non-specific binding
The assays were benchmarked against established reference antibodies such as infliximab, bevacizumab, bococizumab, gantenerumab, and trastuzumab to compare the computational designs directly with approved and clinical-stage molecules.
Role of the RushDATA Platform
RushDATA is Biointron's wet-lab validation service designed for AI-generated antibodies. The platform offers:
- High-throughput expression capabilities reported at over 10,000 antibodies per day
- Turnaround times starting from 2 days for cell-free expression or 3 days for CHO expression
- Binding affinity measurements using BLI or SPR
- Developability profiling using techniques like DSF, PSR-BVP, and AC-SINS
Results are provided as structured datasets with API access intended to feed back into subsequent rounds of AI-guided model design.
Background on Mol-1 and Verification
Molence Bio's Mol-1 project aims at antibody-antigen structure prediction and functional nanobody design. Researchers and interested parties can access the model weights via the official GitHub repository at https://github.com/molence/Mol-1
To verify the original announcement and learn more about the validation platform, readers can consult the official press release on PR Newswire or visit the Biointron RushDATA portal at https://www.biointron.com/antibody-production/rushdata.html
AI-assisted reporting; source claims are attributed and have not been independently verified.



